Wire flash
Tide Pharma acquires industrial site in Hangzhou, plans peptide API line with 3-5 tonne annual capacity
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Tide Pharmaceutical (03880.HK) announced on September 24 that it has completed the acquisition of an industrial land parcel and buildings in the Qiantang District of Hangzhou, China, as part of its strategic capacity expansion for its peptide and oligonucleotide CDMO business. The project, designated as Phase I of the company's scaled CDMO production base, covers approximately 30 mu (about 2 hectares) with existing factory floor space of about 13,500 square meters. Tide plans to build a large-scale peptide active pharmaceutical ingredient (API) production line on the site, with a designed annual capacity of 3-5 tons, though actual output and commissioning will depend on construction, equipment debugging, regulatory approvals, and market demand. The company intends to further integrate an adjacent 56-mu plot in Phase II to create a total 86-mu CDMO production park, aiming to expand capacity and enhance its ability to undertake large commercial projects. The board believes this expansion will support the group's CDMO business development and benefit shareholders.
Source report
Hong Kong, September 24 — Ted Pharma (03880.HK) announced that, as part of its strategic capacity expansion for the Group's peptide and oligonucleotide CDMO business, it has signed an acquisition agreement for an industrial land parcel and property located in the Qiantang District of Hangzhou. The acquisition has been completed as of the date of this announcement, and the site is intended to serve as Phase I of the Group's large-scale CDMO production base.
Project Overview
- Land area: Approximately 30 mu (approx. 2 hectares)
- Existing building area: Approximately 13,500 square meters
- Planned use: Construction of large-scale peptide active pharmaceutical ingredient (API) production lines
- Designed annual production capacity: Estimated at 3–5 tons
The actual production capacity and commissioning schedule will be subject to factors including project construction progress, equipment commissioning, regulatory approvals, and market demand.
Future Expansion Plans
The Group plans to further integrate an adjacent parcel of approximately 56 mu in Phase II, creating a total CDMO production campus spanning approximately 86 mu. This expansion is intended to:
- Further scale up production capacity to meet large-scale demand
- Enhance the Group's ability to undertake large-scale commercial projects
Board Statement
The Board believes that this capacity expansion is aligned with the business needs of the Group's peptide and oligonucleotide CDMO operations. It is expected to strengthen the Group's CDMO service capabilities and capacity-acceptance capacity, thereby serving the overall interests of the Company and its shareholders.
Source
格隆汇Eastern
Part of this Story
**Tide Pharmaceutical Acquires Hangzhou Land for Peptide API Production Base**